Overview

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency

Status:
Active, not recruiting

Trial end date:
2023-09-14

Target enrollment:

Participant gender:

Summary

This study will assess the pharmacokinetics, safety, tolerability, maintenance of virological suppression and patient reported outcomes for participants receiving CAB and RPV LA injections following SC administration in the anterior abdominal wall SC tissue compared with IM administration in the gluteus medius muscle in adult participants living with HIV-1 infection in the FLAIR study (NCT02938520).

Phase:

Phase 3

Details

Lead Sponsor:

ViiV Healthcare

Collaborators:

GlaxoSmithKline
Janssen Pharmaceuticals

Treatments:

Cabotegravir
Rilpivirine